This company has been acquired
Marrone Bio Innovations (MBII) Stock Overview
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MBII Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Marrone Bio Innovations, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$1.50 |
| 52 Week Low | US$0.55 |
| Beta | 0.36 |
| 1 Month Change | -26.10% |
| 3 Month Change | -18.58% |
| 1 Year Change | -43.40% |
| 3 Year Change | -43.80% |
| 5 Year Change | -27.45% |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Shareholder Returns
| MBII | US Chemicals | US Market | |
|---|---|---|---|
| 7D | -19.6% | -0.2% | 0.8% |
| 1Y | -43.4% | -3.5% | 13.7% |
Return vs Industry: MBII underperformed the US Chemicals industry which returned -12.9% over the past year.
Return vs Market: MBII underperformed the US Market which returned -19% over the past year.
Price Volatility
| MBII volatility | |
|---|---|
| MBII Average Weekly Movement | 13.9% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBII's share price has been volatile over the past 3 months.
Volatility Over Time: MBII's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 153 | Kevin Helash | www.marronebio.com |
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health.
Marrone Bio Innovations, Inc. Fundamentals Summary
| MBII fundamental statistics | |
|---|---|
| Market cap | US$145.56m |
| Earnings (TTM) | -US$20.89m |
| Revenue (TTM) | US$44.37m |
Is MBII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBII income statement (TTM) | |
|---|---|
| Revenue | US$44.37m |
| Cost of Revenue | US$17.89m |
| Gross Profit | US$26.48m |
| Other Expenses | US$47.37m |
| Earnings | -US$20.89m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 59.69% |
| Net Profit Margin | -47.08% |
| Debt/Equity Ratio | 139.3% |
How did MBII perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/13 17:59 |
| End of Day Share Price | 2022/07/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marrone Bio Innovations, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Benjamin Kallo | Baird |
| Benjamin Klieve | B. Riley Wealth |